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Norbert Baumgartner, MD,¶ Christopher Genco, MD,¶ Scott Goldman, MD,# Marco Zenati, MD,**
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Objectives We sought to determine whether patients with functional mitral regurgitation (FMR) would benefit from ventricu-
lar reshaping by the Coapsys device (Myocor, Inc., Maple Grove, Minnesota).
Background FMR occurs when ventricular remodeling impairs valve function. Coapsys is a ventricular shape change device placed
without cardiopulmonary bypass to reduce FMR. It compresses the mitral annulus and reshapes the ventricle. We
hypothesized that Coapsys for FMR would improve clinical outcomes compared with standard therapies.
Methods RESTOR-MV (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve) was a ran-
domized, prospective, multicenter study of patients with FMR and coronary disease with core laboratory analysis.
After enrollment, patients were stratified to the standard indicated surgery: either coronary artery bypass graft
alone or coronary artery bypass graft with mitral valve repair. In each stratum, randomization was to either con-
trol (indicated surgery) or treatment (coronary artery bypass graft with Coapsys ventricular reshaping).
Results The study was terminated when the sponsor failed to secure ongoing funding; 165 patients were randomized. Control
and Coapsys both produced decreases in left ventricular (LV) end-diastolic dimension and MR at 2 years (p  0.001);
Coapsys provided a greater decrease in LV end-diastolic dimension (p  0.021). Control had lower MR grades during
follow-up (p  0.01). Coapsys showed a survival advantage compared with control at 2 years (87% vs. 77%)
(hazard ratio: 0.421; 95% confidence interval: 0.200 to 0.886; stratified log-rank test; p  0.038). Complication-
free survival (including death, stroke, myocardial infarction, and valve reoperation) was significantly greater with
Coapsys at 2 years (85% vs. 71%) (hazard ratio: 0.372; 95% confidence interval: 0.185 to 0.749; adjusted log-
rank test; p  0.019).
Conclusions Analysis of RESTOR-MV indicates that patients with FMR requiring revascularization treated with ventricular reshaping
rather than standard surgery had improved survival and a significant decrease in major adverse outcomes. This trial
validates the concept of the ventricular reshaping strategy in this subset of patients with heart failure. (Randomized
Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve [RESTOR-MV]; NCT00120276) (J Am Coll
Cardiol 2010;56:1984–93) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.051r
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1985JACC Vol. 56, No. 24, 2010 Grossi et al.
December 7, 2010:1984–93 The RESTOR-MV Trialapillary muscle displacement tethers leaflets, causing
unctional mitral regurgitation (FMR). Increasing LV
imensions and wall stress in combination with FMR
ncrease the cardiac workload, which further degrades
unction with progression of LV remodeling (1–3).
Current treatments for LV dysfunction with FMR in-
lude medical therapy and surgery. Medical therapy includes
nloading the ventricle and down-regulating the metabolic
athways that cause progression of ventricular failure; this
nfortunately has limited effects on the progression of FMR
4). For patients with viable ischemic myocardium, revas-
ularization is a first step, with the objectives of preventing
urther damage, relieving the ischemia that may contribute
o FMR, and perhaps arresting or reversing the remodeling
rocess. The effect of correcting ischemia on mitral valve
MV) function has been unpredictable and often transient,
eaving the majority of patients with residual, recurrent, or
rogressive MR (5). Alternatively, FMR is treated by MV
urgery, consisting of either MV repair or prosthetic re-
lacement. MV repair involves placing an undersized annu-
oplasty device to increase the coaptive leaflet margin,
liminate regurgitation, and achieve a durable repair (6).
lthough MV repair is generally superior to replacement,
eplacement is sometimes recommended in patients with
ignificant leaflet tethering who are considered at high risk
f recurrence (7). Current operations have significant pro-
edural risk in the FMR population, and late outcomes
emain guarded (8). Due to the risk associated with current
herapies, the vast majority of FMR patients are not treated
9). With whichever treatment, percutaneous coronary in-
ervention, coronary artery bypass graft (CABG) alone, or
ABG plus MV repair, the 1-year mortality rate is unfor-
unately approximately 20% (1,8,10–13).
As previously reported (14), Coapsys (Myocor, Inc.,
aple Grove, Minnesota) was developed to treat FMR.
oapsys reshapes the ventricle, compressing the mitral
nnulus and subvalvular apparatus to decrease FMR. This
ecreases LV wall stress and induces positive ventricular
emodeling (15). Coapsys consists of posterior and anterior
xtracardiac epicardial pads connected by a flexible, trans-
entricular subvalvular chord (Fig. 1). The posterior pad
Figure 1 Coapsys Device Is Composed of a
Dual-Headed Posterior Pad and Single Anterior Pad
The suture cord is shortened after placement to reshape
the left ventricle and decrease functional mitral regurgitation.ompresses both the mitral an-
ular and papillary muscle levels
Fig. 2). The device is sized intra-
peratively by shortening the
hordal length of the device, thus
rawing the pads together. Echo-
ardiography simultaneously assesses
R reduction. Implantation is per-
ormed without cardiotomy or car-
iopulmonary bypass.
An initial feasibility study indi-
ated that Coapsys significantly
ecreased FMR and improved
ollow-up New York Heart Asso-
iation (NYHA) functional class
14). On the basis of these find-
ngs, prospective evaluation of Co-
psys was initiated under U.S.
ood and Drug Administration supervision.
ethods
tudy design. RESTOR-MV (Randomized Evaluation of
Surgical Treatment for Off-Pump Repair of the Mitral
alve) was a prospective, randomized, multicenter trial
Online Appendix A) comparing Coapsys with a standard
f care control in patients with FMR undergoing CABG.
atients were allocated by the surgeon per protocol to a
tandard of care stratum, either CABG with MV repair
CABGMV repair) or CABG alone. In the CABGMV
epair stratum, subjects were randomized 1:1 to undergo
ABG with mitral ring annuloplasty (control) or undergo
ABG  Coapsys (treatment). In the CABG alone stratum,
ubjects were randomized 1:1 to CABG alone (control) or
ABG  Coapsys (treatment) (Fig. 3).
Figure 2 Coapsys Ventricular Effect
(Left) Long-axis view and positioning of device. (Right) Relationships
of posterior pads to posterior mitral annulus and papillary muscles.
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CI  confidence interval
FMR  functional mitral
regurgitation
HR  hazard ratio
LV  left ventricular
MI  myocardial infarction
MR  mitral regurgitation
MV  mitral valve
NYHA  New York Heart
Association
PAE  primary adverse
event
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1986 Grossi et al. JACC Vol. 56, No. 24, 2010
The RESTOR-MV Trial December 7, 2010:1984–93This study had the approval of each center’s institutional
eview board. MR was evaluated by a core laboratory (Mayo
linic) by 1 of 2 observers. MR was graded as 1 (mild), 2
moderate), 3 (moderate to severe), or 4 (severe).
election of patients and randomization. Patients re-
erred for CABG were screened for FMR. Enrollment
riteria included moderate or worse MR assessed with
-dimensional echocardiography, the need for concomitant
ABG, and LV ejection fraction 25%. Patients were
xcluded if they had a structural abnormality of the MV,
symptomatic moderate MR, transmural myocardial infarc-
ion (MI) within 30 days, or NYHA functional class IV.
omplete study criteria are provided in Online Appendix B.
atient comorbidities and the degree of MR were used by
he surgeon to decide stratum assignment (CABG  MV
epair vs. CABG alone); the significant majority of the
atients were assigned to the CABG MV repair stratum.
urgeons had the option of placing patients with significant
R and specific contraindications to cardiopulmonary by-
Figure 3 RESTOR-MV Trial Consort Flowchart
CABG  coronary artery bypass graft; FDA  U.S. Food and Drug Administration; Mass in the CABG alone stratum. After stratum assignment tnd confirmation of FMR with intraoperative transesoph-
geal echocardiography, randomization was performed.
reatment. All patients receiving Coapsys were part of the
tudy; no patients were excluded from this analysis. All
urgeons were required to follow the randomized assignment
nless a safety concern was documented. This protocol did not
estrict subsequent alternative treatments using standard ther-
pies. Conversions from the treatment arm to the control arm
ere permitted for safety reasons and tracked.
rimary and secondary outcomes. Patients were evaluated
t baseline; intraoperatively; before hospital discharge; at 3,
, 12, 18, and 24 post-operative months; and annually
hereafter. All-cause mortality, primary adverse events
PAEs), and MR decrease were the primary outcomes.
AEs were defined as death (cardiac and noncardiac),
troke, MI, reoperation (for bleeding, valvular dysfunction
r life-threatening arrhythmias), and mechanical device
ailure. Adverse event types are summarized in Online
ppendix C. Secondary outcomes included NYHA func-
itral regurgitation; PAE  primary adverse event.R  mional class.
S
f
t
P
s
t
a
a
m
t
s
a
a
p
a
e
c
v
m
p
S
d
A
p
h
e
C
a
l
P
t
s
M
t
i
c
e
c
t
R
S
2
M
(
a
a
S
D
i
c
w
t
a
r
A
T
a
e
a
f
a
r
r
w
w
F
t
2
a
C
c
9
l
o
T
m
c
C
9
P
v
(
0
M
s
w
0
p
p
r
m
a
a
s
O
M
1
r
m
t
e
i
0
C
l
1987JACC Vol. 56, No. 24, 2010 Grossi et al.
December 7, 2010:1984–93 The RESTOR-MV Trialtatistical analysis. The study was designed to test nonin-
eriority of Coapsys therapy at 12 months as measured by
he change in MR (efficacy hypothesis) and freedom from
AEs (safety hypothesis) in the CABG  MV repair
tratum. The original design (based on Bayesian simula-
ions) had planned interim analyses with 75 patients in each
rm of the CABG  MV repair stratum, and again at 100
nd 125 patients. RESTOR-MV was terminated approxi-
ately at the first planned interim analysis with 150 patients in
he primary stratum. Because the primary focus was patient
urvival randomized to control versus Coapsys, we considered
Pocock boundary based on a 3-look interim design to provide
measure of statistical significance based on an overall 2-sided
value of 0.05 (power  90%) to interpret the reported
nalyses. At first look, with 60% of all planned patients
ntered, we can detect a hazard ratio (HR) for Coapsys versus
ontrol of 0.49 or 2.02 (  0.035; computations EAST
ersion 5.2, Cytel, Inc., Boston, Massachusetts).
Baseline characteristics that differed between the 2 treat-
ents (p  0.05) were included in the survival analyses. All
atients are included as randomized (intention-to-treat).
urvival time was measured from the date of treatment until
eath or censored at the date of last follow-up for survivors.
stratified log-rank test evaluated differences in survival
robabilities for the 2 treatment arms. Cox proportional
azards models (with and without covariates) were fitted to
stimate the stratified hazard ratio for patient survival in
oapsys compared with control. Unstratified log-rank tests
nd HRs were estimated for each stratum separately (On-
ine Appendix D). Similar analyses were conducted for
AEs and by actual treatment rendered (as treated).
MR reduction at 12 months was analyzed using a 2-sided
test for the CABG  MV repair and CABG alone strata
eparately. To compare the effects of treatment over time on
R, random-effects linear regression models were fitted
hat included as independent variables treatment, time, and
nteraction between treatment and time. NYHA functional
lass change was analyzed using generalized estimating
quation models. The probabilities of NYHA functional
lasses having lower values were modeled; the effects of
reatment, time, and their interaction were tested.
esults
tudy population. Between April 2003 and September
008, 165 patients were randomized: 149 in the CABG 
V repair stratum and 16 in the CABG alone stratum.
Fig. 3). The study population was 77% male and the mean
ge was 65.3 years; a list of demographic data by stratum
nd randomized treatment is shown in Table 1.
urgical procedures. CONVERSIONS/OPERATIVE PROTOCOL
EVIATIONS. Intraoperative conversions from the random-
zed therapy to an alternative occurred where clinically indi-
ated for patient safety. There were 2 (2.67%) control patients
ho converted to CABG  MV replacement and 7 (9.45%)reatment patients converted to an alternative (4 to CABG  cnnuloplasty, 1 to CABGMV replace, 2 to CABG only) after
andomization occurred (Online Appendix E).
LTERNATIVE TREATMENT FOLLOWING STUDY PROCEDURE.
hree patients in follow-up (1 in control and 2 in treatment,
ll in the CABG  MV repair stratum) underwent reop-
ration for severe MR. Patients who received subsequent
lternative treatment remained in the study and were
ollowed per the study protocol to allow intention-to-treat
nalyses. The reoperated-on control patient received an MV
eplacement. Of the 2 treatment patients who underwent
eoperation, 1 underwent mitral annuloplasty and 1 under-
ent MV replacement. In both cases, the Coapsys device
as left implanted.
ollow-up. The study was prematurely terminated after
he sponsor failed to secure ongoing funding in October
008 with 165 patients randomized. An intention-to-treat
nalysis of all patients showed a survival advantage for the
oapsys treatment with a 2-year survival rate of 87%
ompared with 77% for the control patients (HR: 0.421;
5% confidence interval [CI]: 0.200 to 0.866, stratified
og-rank test; p  0. 038) (Fig. 4); at 2 years, 18 deaths had
ccurred in the control arm and 10 in the treatment arm.
he mean follow-up interval was 28.3 months, with a
edian of 27.2 months. As-treated analysis of all patients
onfirmed the advantage in overall survival at 2 years for the
oapsys group (treatment, 89%; control, 76%) (HR: 0.378;
5% CI: 0.174 to 0.824; log-rank test; p  0.020).
AEs. Intention-to-treat analysis of complication-free sur-
ival from any PAE was significantly greater with Coapsys
control, 63% vs. treatment, 76%) (HR: 0.461; 95% CI:
.258 to 0.825; adjusted log-rank test; p  0.022) (Fig. 5).
V-related complication-free survival (including death,
troke, MI, and MV reoperation) was significantly greater
ith Coapsys at 2 years (85% vs. 71%) (HR: 0.372; 95% CI:
.185 to 0.749, adjusted log-rank test; p 0.019). The Cox
roportional hazard model with both treatment and sex as
redictor variables was also fitted, and the hazard of MV-
elated complications was also significantly greater for fe-
ale patients (HR: 2.34; 95% CI: 1.16 to 4.71). As-treated
nalysis of complication-free survival showed a similar
dvantage to Coapsys treatment. PAE occurrences are
hown in Online Appendix F.
ther outcomes. In the CABG  MV repair stratum,
R at 1 and 2 years was 0.52  0.66 and 0.35  0.63 and
.4  1.00 and 1.2  0.97 for control and treatment,
espectively (Table 2). MR decrease from baseline to 12
onths in the control arm was significantly greater than in
he treatment arm (p  0.0001). Based on the random-
ffects model, the time effect and the treatment  time
nteraction were both statistically significant (each p 
.0001); the effect of treatment alone was not. In the
ABGMV repair stratum, MR at 2 years was decreased at
east 2 grades or was grade 1 or less in 92.0% of the control arm
ompared with 66.7% in the treatment arm (p  0.02).
P1988 Grossi et al. JACC Vol. 56, No. 24, 2010
The RESTOR-MV Trial December 7, 2010:1984–93atient Demographic and Disease Characteristics by Randomized Treatment Group and StratumTable 1 Patient Demographic and Disease Characteristics by Randomized Treatment Group and Stratum
Control Treatment
p Value (2-Sided, t Test)No. Known (n  75) Mean  SD No. Known (n  74) Mean  SD
CABG  MV Repair Stratum
Age, yrs 73 65.6 8.72 73 64.7 9.12 0.55
LVEF, % 69 38.3 10.3 69 35.4 10.0 0.10
Weight, kg 74 82.2 19.8 73 84.2 21.6 0.55
MR, 0 to 4 72 2.54 0.804 72 2.40 0.867 0.32
CABG Alone Stratum
Age, yrs 8 63.9 13.8 8 69.9 9.44 0.335
LVEF, % 7 35 8.7 6 39.2 5.8 0.33
Weight, kg 8 81.5 17.9 8 74.0 17.1 0.40
MR, 1 to 3 7 2.00 0.577 6 2.00 0.632 0.99
Control, Frequency (Proportion) Treatment, Frequency (Proportion)
p Value
(Fisher Exact Test, 2-Sided)CABG  MV Repair Stratum (n  75) CABG  MV Repair Stratum (n  74)
Sex Male: 63 (0.84) Male: 49 (0.66) 0.019
Female: 11 (0.15) Female: 24 (0.32)
NA: 1 (0.014) NA: 1 (0.014)
NYHA functional class 1:5 (0.067) 1: 4 (0.054) 0.93
2: 31 (0.413) 2: 30 (0.405)
3: 36 (0.480) 3: 38 (0.514)
NA: 3 (0.040) NA: 2 (0.027)
No. of grafts performed 1: 8 (0.107) 1: 12 (0.162) 0.84
2: 18 (0.240) 2: 15 (0.203)
3: 35 (0.467) 3: 30 (0.405)
4: 11 (0.147) 4: 15 (0.203)
5: 1 (0.013) 5: 1 (0.014)
6: 1 (0.013) 6: 0 (0)
NA: 1 (0.013) NA: 1 (0.014)
Diabetes Yes: 42 (0.56) Yes: 30 (0.405) 0.19
No: 31 (0.413) No: 42 (0.568)
NA: 2 (0.027) NA: 2 (0.027)
Renal insufficiency Yes: 20 (0.267) Yes: 18 (0.243) 0.93
No: 54 (0.720) No: 55 (0.743)
NA: 1 (0.013) NA: 1 (0.014)
PVD Yes: 16 (0.213) Yes: 12 (0.162) 0.62
No: 55 (0.733) No: 56 (0.757)
NA: 4 (0.053) NA: 6 (0.081)
History of CHF Yes: 48 (0.640) Yes: 51 (0.689) 0.85
No: 25 (0.333) No: 21 (0.284)
NA: 2 (0.027) NA: 2 (0.027)
History of MI Yes: 44 (0.587) Yes: 45 (0.608) 0.77
No: 23 (0.307) No: 24 (0.324)
NA: 8 (0.107) NA: 5 (0.068)
History of stroke Yes: 6 (0.080) Yes: 7 (0.095) 0.52
No: 65 (0.867) No: 66 (0.892)
NA: 4 (0.053) NA: 1 (0.014)
Previous CABG Yes: 0 (0) Yes: 2 (0.027) 0.52
No: 73 (0.973) No: 71 (0.959)
NA: 2 (0.027) NA: 1 (0.014)
History of PCI Yes: 11 (0.147) Yes: 15 (0.202) 0.59
No: 62 (0.827) No: 58 (0.784)
NA: 2 (0.027) NA: 1 (0.014)
History of atrial fibrillation Yes: 20 (0.267) Yes: 12 (0.162) 0.31
No: 47 (0.627) No: 54 (0.730)
NA: 8 (0.107) NA: 8 (0.108)Continued on next page
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December 7, 2010:1984–93 The RESTOR-MV TrialAs-treated analysis revealed an initial decrease in LV
nd-diastolic dimension with both CABG  MV repair
5.9  0.7 cm to 5.6  0.9 cm) and CABG  Coapsys
herapies (6.0  0.8 cm to 5.4  0.8 cm) (p  0.001,
epeated-measures analysis of variance) with a significantly
reater decrease with the CABG Coapsys treatment (p
.02). Coapsys started with an average resting transventricu-
ar chordal length of 8.6  1.5 cm and was shortened to
.4  1.1 cm (25.3%) (directly measured from a sizing
nstrument).
Percentages of patients in the CABGMV repair stratum
ith NYHA functional class improvement of 1 at 1 and 2
ontinuedTable 1 Continued
Control, Frequency (Proportion)
CABG  MV Repair Stratum (n  75)
Cardiopulmonary bypass used Yes: 74 (0.987)
No: 0 (0)
NA: 1 (0.013)
CABG Alone Stratum (n  8)
Sex Male: 7 (0.875)
Female: 1 (0.125)
NYHA functional class 1: 0 (0)
2: 2 (0.250)
3: 5 (0.625)
NA: 1 (0.125)
No. of grafts performed 1: 1 (0.0625)
2: 3 (0.188)
3: 2 (0.125)
4: 2 (0.125)
5: 0 (0)
Diabetes Yes: 3 (0.375)
No: 5 (0.625)
Renal insufficiency Yes: 1 (0.125)
No: 7 (0.875)
PVD Yes: 3 (0.375)
No: 5 (0.625)
History of CHF Yes: 5 (0.625)
No: 2 (0.25)
NA: 1 (0.125)
History of MI Yes: 7 (0.875)
No: 1 (0.125)
History of stroke No: 6 (0.75)
NA: 2 (0.25)
Yes: 0 (0)
Previous CABG Yes: 1 (0.125)
No: 7 (0.875)
History of PCI Yes: 1 (0.125)
No: 7 (0.875)
History of atrial fibrillation Yes: 1 (0.125)
No: 3 (0.375)
NA: 4 (0.5)
Cardiopulmonary bypass used Yes: 0 (0)
No: 8 (1)
ABG coronary artery bypass graft; CHF coronary heart disease; LVEF left ventricular ejectio
YHA  New York Heart Association; PCI  percutaneous coronary intervention; PVD  peripheraears from baseline are 65.9% and 72.0%, respectively, for the sontrol arm and 70.6% and 79.4%, respectively, for the
reatment arm (Online Appendix G). Although the effect of
ime was significant (p  0.0001, generalized estimating
quation), the effect of group was not (p  0.86). In each
roup, 73% of deaths were truly cardiac in origin.
iscussion
e compared the survival outcomes of standard of care
ontrols with that of the Coapsys device in patients under-
oing CABG with moderate or worse MR. Results dem-
nstrate that patients undergoing a strategy of ventricular
Treatment, Frequency (Proportion)
p Value
(Fisher Exact Test, 2-Sided)CABG  MV Repair Stratum (n  74)
Yes: 23 (0.311) 2.2e-16
No: 48 (0.649)
NA: 3 (0.041)
CABG Alone Stratum (n  8)
Male: 6 (0.75) 0.99
Female: 2 (0.25)
1: 1 (0.125) 0.20
2: 5 (0.625)
3: 2 (0.25)
NA: 0 (0)
1: 1 (0.0625) 0.89
2: 1 (0.0625)
3: 3 (0.188)
4: 2 (0.125)
5: 1 (0.0625)
Yes: 4 (0.5) 0.99
No: 4 (0.5)
Yes: 2 (0.25) 0.99
No: 6 (0.75)
Yes: 3 (0.375) 0.99
No: 5 (0.625)
Yes: 3 (0.375) 0.31
No: 5 (0.625)
NA: 0 (0)
Yes: 7 (0.875) 0.99
No: 1 (0.125)
No: 6 (0.75) 0.99
NA: 2 (0.25)
Yes: 0 (0)
Yes: 0 (0) 0.99
No: 8 (1)
Yes: 1 (0.125) 0.99
No: 7 (0.875)
Yes: 1 (0.125) 0.99
No: 2 (0.25)
NA: 5 (0.625)
Yes: 0 (0) 0.99
No: 8 (1)
on; MImyocardial infarction; MRmitral regurgitation; MVmitral valve; NA not available;
lar disease.hape change with the Coapsys device in combination with
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The RESTOR-MV Trial December 7, 2010:1984–93ABG had improved survival at 2 years. In the surviving
atients of the CABG  MV repair stratum, both the
ontrol and Coapsys arms had significant and similar
mprovements in NYHA functional class. Superior safety
f the procedure was also documented, with fewer PAEs
n the Coapsys treatment group. Because a significant
ortion of PAEs occurred in the early perioperative time
Figure 4 Overall Survival, Intention-to-Treat Analysis: Control V
(A) CABG  MV repair stratum. (B) All patients; adjusted log-rank. CI  confidencrame, Coapsys may confer an advantage from its off- hump, less invasive placement. The ability to conduct a
igher-risk operation, such as combined MV repair and
ABG without the need for cardiopulmonary bypass,
ay convey the previously reported benefits of isolated
ff-pump coronary revascularization, such as decreased
notrope dependence, decreased bleeding and transfusion,
aster intensive care unit recovery, and shorter length of
Treatment
val; other abbreviations as in Figure 3.ersus
e interospital stay (16).
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December 7, 2010:1984–93 The RESTOR-MV TrialThe survival benefit in the Coapsys group may result from
everal factors, including the lower PAE rate and the
ossible benefit of the combined MR treatment in conjunc-
ion with LV wall stress reduction. Although the control
nnuloplasty stratum did show a greater decrease in MR,
his did not translate into improved survival or better
Figure 5 Overall Survival, As-Treated Analysis: Control Versus C
(A) CABG  MV repair stratum. (B) All patients; adjusted log-rank. Abbreviations aymptom reduction. It is most likely that the survival benefit tas related to the ventricular shape change effected by the
evice. The Coapsys has an acute positive reshaping effect
n the entire ventricle, whereas the effect of traditional
nnuloplasty is limited to the base of the ventricle (17). This
ffect was demonstrated again in the current trial with twice
he initial decrease in LV end-diastolic dimension in pa-
ys
igures 3 and 4.oaps
s in Fients receiving CABG  Coapsys compared with those
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The RESTOR-MV Trial December 7, 2010:1984–93eceiving CABG  MV repair. It is additionally possible
hat the long-term survival benefit seen with the device is
ue to a global and progressive reversal of LV remodeling,
hich was seen in the earlier TRACE (Treatment of
unctional Mitral Regurgitation without Atriotomy or
PB Clinical Evaluation) study (15).
Contrasting “negative” results of ventricular volume re-
uction in the recent STICH (Surgical Treatment for
schemic Heart Failure) trial (18) deserve comment. The
oapsys method decreases wall stress by changing the
hamber shape rather than decreasing chamber size by
xcluding a dyskinetic wall. The STICH study postulated
hat the failure to demonstrate clinical benefit was related to
ecreased diastolic distensibility. In contrast, the Coapsys
evice does not create the same diastolic impairment for the
ame level of LV radius/wall stress reduction (19,20).
dditionally, the effect of inflow restriction is not well
nderstood when restrictive annuloplasty is used to treat
MR; one study demonstrated dynamic mitral stenosis after
uch treatment (21). This has not been seen with the
oapsys device. It has been speculated that lack of clinical
quipoise in patient recruitment and the failure to achieve
he targeted 30% ventricular volume decrease led to the
TICH trial results, which contradict earlier experience
22). Finally, the greater invasiveness of the STICH ap-
roach compared with Coapsys may contribute to the
ifference in outcome for these LV remodeling approaches.
Two questions arise when looking at these data: Are the
ontrol outcomes representative of previous reports? Would
n alternative strategy of not performing MV repair result in
etter survival? Recent publications on CABG and MV
epair for FMR indicate that mortality rates are very similar
o those in the RESTOR-MV CABG  MV repair
tratum, with a weighted perioperative mortality rate of 8%
nd 1-year mortality rate of 19% (1,8,10–13,23–27). For
schemic FMR patients, medical management has poorer
ore Laboratory Mitral Insufficiency Grades (0 to 4)y Randomized Treatme t Group and Stratumver Time
Table 2
Core L boratory Mitr l Insufficiency Grades (0 to 4)
by Randomized Treatment Group and Stratum
Over Time
Time
Control Treatment
MR Grade MR Grade
Mean SD n Mean SD n
CABG  MV Repair Stratum
Baseline 2.54 0.80 72 2.40 0.87 72
6 months 0.63 0.82 51 1.49 1.07 57
12 months 0.52 0.66 46 1.42 1.00 52
24 months 0.35 0.63 26 1.24 0.97 33
CABG Alone Stratum
Baseline 2.00 0.58 7 2.00 0.63 6
6 months 1.33 0.82 6 1.29 0.95 7
12 months 1.17 0.75 6 1.14 0.90 7
24 months 1.33 0.58 3 1.29 0.76 7
bbreviations as in Table 1.urvival than with revascularization or repair strategies
Y1,28). Additionally, no survival advantage has been dem-
nstrated when comparing FMR patients undergoing PCI,
ABG alone, or CABG  MV repair (1,28,29). The
ESTOR-MV study suggests that decreasing the MR and
eshaping the ventricle with a less invasive therapy have a
urvival benefit that was not noted in previous studies of
standard” surgical therapy for FMR. In this high-risk
atient cohort, the observed survival benefit may be due to
combination of a less invasive procedure, fewer peripro-
edural complications, and direct ventricular wall stress
eduction.
tudy limitations. The main limitation was that the study
as terminated early, which was beyond the control of the
nvestigators. However, recruitment was very near the U.S.
ood and Drug Administration pre-specified “first look.”
he significant outcomes of the intention-to-treat analysis
ere reinforced by similar, stronger outcomes in the as-
reated analysis. Additionally, this series did not include
atients with an ejection fraction 25%; this restriction was
et in place to limit the perceived high early mortality in
uch patients, which would limit the discriminatory power
f the device trial. This trial did not perform myocardial
iability testing, and it was not always possible to distinguish
ymptoms of coronary disease from symptoms of MR.
lthough this may have an impact on overall survival for all
atients, this could not explain the differential outcomes
etween randomized treatments in such a large patient
opulation, particularly when all patients were being revas-
ularized. The echocardiography laboratory was not blinded
o therapy; interobserver and intraobserver variability is not
eported in this study.
onclusions
e have described a novel off-pump surgical therapy, Coapsys,
hich simultaneously reshapes both the left ventricle and the
itral annulus with the intent of treating FMR. On the basis
f intention-to-treat analyses, the RESTOR-MV trial found
hat patients with FMR who required revascularization and
ere treated with ventricular reshaping rather than the stan-
ard surgical approach had HRs of less than one-half for both
ortality and major adverse outcomes. This unique approach
o reshaping the left ventricle and treating the valve has effected
meaningful impact on the clinical outcomes of patients with
MR.
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